NCT01614041

Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder

Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder: a Multi-center, Randomized, Usual Dose-controlled Trial

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 274 (actual)
• Sponsor: Sumitomo Pharma (Suzhou) Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of comparative high dose Tandospirone Citrate in the treatment of patients with generalized anxiety disorder.

Conditions

• Generalized Anxiety Disorder

Interventions

Type	Name	Description
DRUG	Usual dose treatment of Tandospirone	Usual dose treatment of Tandospirone, oral, 30 mg/day
DRUG	Comparative high dose of tandospirone treatment	Comparative high dose of tandospirone treatment, oral, 60 mg/day

Timeline

• Start date: 2012-01-10
• Primary completion: 2018-09-11
• Completion: 2019-07-01
• First posted: 2012-06-07
• Last updated: 2020-01-07

Locations

1 site across 1 country: China